PT - JOURNAL ARTICLE AU - José Patané AU - Vincent Viala AU - Loyze Lima AU - Antonio Martins AU - Claudia Barros AU - Elaine Marqueze AU - Jardelina Bernardino AU - Debora Moretti AU - Svetoslav Slavov AU - Rafael Santos AU - Evandra Rodrigues AU - Elaine Santos AU - Ricardo Brassaloti AU - Raquel Cassano AU - Pilar Mariani AU - João Kitajima AU - Bibiana Santos AU - Patricia Assato AU - Felipe Costa AU - Mirele Poleti AU - Jessika Lesbon AU - Elisangela Mattos AU - Cecilia Banho AU - Lívia Sacchetto AU - Marília Moraes AU - Melissa Palmieri AU - Fabiana Silva AU - Rejane Grotto AU - Jayme Souza-Neto AU - Marta Giovanetti AU - Luiz Alcantara AU - Maurício Nogueira AU - Heidge Fukumasu AU - Luiz Coutinho AU - Rodrigo Calado AU - Simon Kashima AU - Raul Neto AU - Dimas Covas AU - Carolina Sabbaga AU - Sandra Coccuzzo TI - SARS-CoV-2 Delta variant of concern in Brazil - multiple introductions, communitary transmission, and early signs of local evolution AID - 10.1101/2021.09.15.21262846 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.15.21262846 4099 - http://medrxiv.org/content/early/2021/09/22/2021.09.15.21262846.short 4100 - http://medrxiv.org/content/early/2021/09/22/2021.09.15.21262846.full AB - The dissemination of the Delta VOC in Brazil is still unclear, despite the frequent reports of isolated cases from different Brazilian states. In this report we characterize the dissemination of the Delta VOC in Brazil and where the introductions of this lineage fall within the global Delta phylogeny. We also examined the mutational profile of the largest clade within the Brazilian Delta VOCs, with a focus on samples which were obtained in the State of São Paulo, and especially in the city of São Paulo, the largest metropolis of South America, and a national and international transportation hub.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCAAE: 50367721.7.1001.5440Funding StatementButantan Foundation, Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Grant Numbers: 2020/10127; 2020/06441-2), Fundacao Hemocentro Ribeirao Preto, Pan American Health Organization (OPAS)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Ethics Committee of the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo (CAAE: 50367721.7.1001.5440).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI am making available all data referred to in the manuscript in the form of tables (either regular os supplementary).